Donald Trump continues to increase tariffs on foreign products exported to the USA. In China and Europe, companies are worried. In Haute-Saône, Crossject, a company that has signed a $155 million contract with the US health administration, is not yet affected. What is this contract for? Let us explain.
This is a big contract. A huge contract for Crossject based in Dijon in Côte-d’Or and Arc-les-Gray in Haute-Saône. $155 million to provide the US health administration with a needle-free auto-injector. A unique system in the world that allows for emergency intervention within the armed forces in case of a biological attack. The system, called ZENEO, still needs to receive FDA approval by mid-2025.
The auto-injector developed by Crossject.
•
© Laurent Brocard – France 3 Franche-Comté
Could the massive contract between Crossject and the US health administration, BARDA (Biomedical Advanced Research and Development Authority), be affected by the increase in tariffs or potentially be called into question? Patrick Alexandre, President and founder of Crossject, remains optimistic. «It’s too early to know what will happen. We are positioned on a product ordered by the American administration to protect American lives, so we’ll see how it goes, but they will surely find a solution so as not to penalize themselves, especially since there is no American solution to address the issue we cover, which is injecting a product in case of a chemical terrorist attack on American soil,» says the leader to our journalist Emmanuel Deshayes.
The American order for this auto-injector amounts to nearly 800,000 units on «a contract that can reach $150 million,» adds Patrick Alexandre. «We have three years to deliver, everything is set to start this year.» 35 jobs are at stake in Arc-les-Gray where the auto-injectors are produced.
The auto-injector developed by Crossject allows for emergency treatment. «Today, having a means to administer medication deep into the muscle, even through clothing in a fraction of a second, we are the only ones in the world to offer this. The liquid will come out on its own at over 500 km/h, and the speed will be sufficient to penetrate the tissues,» explains the leader of Crossject. The US health administration was interested in this process a few years ago and approached this company from Bourgogne-Franche-Comté. Crossject has a site in Dijon and another in Arc-les-Gray in Haute-Saône. Le système ZENEO de Crossject doit encore recevoir l’approbation de la FDA, la Food and Drug Administration, d’ici mi-2025.
Le dirigeant de Crossject, Patrick Alexandre, reste optimiste quant à l’impact potentiel des droits de douane sur le contrat signé avec la BARDA. Ce contrat prévoit la livraison de près de 800 000 auto-injecteurs pour un montant pouvant atteindre 150 millions de dollars. Crossject dispose de trois ans pour remplir cette commande, qui pourrait créer 35 emplois à Arc-les-Gray.
L’auto-injecteur développé par Crossject permet une administration rapide de médicaments en cas d’urgence, ce qui a suscité l’intérêt de l’administration de santé américaine. La société, basée en Bourgogne-Franche-Comté, est la seule à proposer cette technologie.
Malgré une baisse de 50% de son cours en bourse en un mois, due en partie aux annonces de Donald Trump, Crossject reste confiant. Les tensions commerciales internationales, notamment entre les États-Unis, la Chine et l’Union européenne, pourraient avoir un impact sur l’entreprise et ses activités. Elle propose également des droits allant jusqu’à 25% sur le bois, les motos, les produits plastiques et les équipements électriques.
SOURCE
Deja una respuesta